Abstract
ObjectivesTo describe trajectories in melanoma survivors’ adherence to monthly total skin self-examination (TSSE) over 12 months, and to investigate whether adherence trajectories can be predicted from demographic, cognitive or emotional factors at baseline.DesignA longitudinal observational study nested within the intervention arm of the ASICA (Achieving Self-Directed Integrated Cancer Aftercare) randomised controlled trial.SettingFollow-up secondary care in Aberdeen and Cambridge UK.Participantsn=104 adults (48 men/56 women; mean age 58.83 years, SD 13.47, range 28–85 years; mean Scottish Index of Multiple Deprivation score 8.03, SD 1.73, range 2–10) who had been treated for stage 0–IIC primary cutaneous melanoma in the preceding 60 months and were actively participating in the intervention arm of the ASICA trial.InterventionsAll participants were using the ASICA intervention—a tablet-based intervention designed to support monthly TSSE.Primary and secondary outcome measuresThe primary outcome was adherence to guideline recommended (monthly) TSSE over 12 months. This was determined from time-stamped TSSE data recorded by the ASICA intervention app.ResultsLatent growth mixture models identified three TSSE adherence trajectories (adherent −41%; drop-off −35%; non-adherent −24%). People who were non-adherent were less likely to intend to perform TSSE as recommended, intending to do it more frequently (OR=0.21, 95% CI 0.06 to 0.81, p=0.023) and were more depressed (OR=1.31, 95% CI 1.06 to 1.61, p=0.011) than people who were adherent. People whose adherence dropped off over time had less well-developed action plans (OR=0.78, 95% CI 0.63 to 0.96, p=0.016) and lower self-efficacy about TSSE (OR=0.92, 95% CI 0.86 to 0.99, p=0.028) than people who were adherent.ConclusionsAdherence to monthly TSSE in people treated for melanoma can be differentiated into adherent, drop-off and non-adherent trajectories. Collecting information about intentions to engage in TSSE, depression, self-efficacy and/or action planning at outset may help to identify those who would benefit from additional intervention.Trial registration numberClinicalTrials.gov Registry (NCT03328247).
Reference49 articles.
1. Cancer Research UK . Melanoma skin cancer statistics 2015-17. Available: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer
2. Follow-up schedules after treatment for malignant melanoma
3. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma;DiFronzo;Ann Surg Oncol,1999
4. National Institute for Health and Care Excellence (NICE) . Melanoma: assessment and management (NG14; 2015). Available: https://www.nice.org.uk/guidance/ng14
5. Health Improvement Scotland . SIGN QRG 146 cutaneous melanoma, 2016. Available: https://www.sign.ac.uk/assets/qrg146.pdf